Market-access firms have become primary takeover targets in the healthcare industry as they are one of the most sought-after subsegments of pharma commercialization. Market access is the process where biopharma companies negotiate reimbursement rates for their products. Amidst a healthcare acquisition spree, more consultancies specializing in evidence communication are in demand. Between 2020 and 2022, PE-backed buyers bought several smaller companies, but deals have slowed this year. Platforms like Fingerpaint Group and Lumanity have made multiple acquisitions. This phenomenon is due to research, development, regulatory, and marketing trends that have made market-access expertise highly coveted. The passage of the Inflation Reduction Act could fuel this demand as it allows Medicare to negotiate prices, prompting companies to gather more evidence of their drug’s positive impact on health outcomes prior to launch.
To read more, click here.
[Source: MM+M, August 4th, 2023]